271 related articles for article (PubMed ID: 32762488)
1. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment.
Dersch R; Wehrum T; Fähndrich S; Engelhardt M; Rauer S; Berger B
Mult Scler; 2020 Sep; 26(10):1264-1266. PubMed ID: 32762488
[TBL] [Abstract][Full Text] [Related]
2. Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression.
Carandini T; Pietroboni AM; Sacchi L; De Riz MA; Pozzato M; Arighi A; Fumagalli GG; Martinelli Boneschi F; Galimberti D; Scarpini E
Mult Scler; 2020 Sep; 26(10):1268-1269. PubMed ID: 32463329
[No Abstract] [Full Text] [Related]
3. Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice.
De Angelis M; Petracca M; Lanzillo R; Brescia Morra V; Moccia M
Mult Scler Relat Disord; 2020 Oct; 45():102452. PubMed ID: 32823148
[TBL] [Abstract][Full Text] [Related]
4. COVID-19 in MS: Initial observations from the Pacific Northwest.
Bowen JD; Brink J; Brown TR; Lucassen EB; Smoot K; Wundes A; Repovic P
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32457226
[No Abstract] [Full Text] [Related]
5. A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.
Valencia-Sanchez C; Wingerchuk DM
Mult Scler Relat Disord; 2020 Jul; 42():102182. PubMed ID: 32416330
[TBL] [Abstract][Full Text] [Related]
6. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
Safavi F; Nourbakhsh B; Azimi AR
Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
[TBL] [Abstract][Full Text] [Related]
7. Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic.
Ghajarzadeh M; Mirmosayyeb O; Barzegar M; Nehzat N; Vaheb S; Shaygannejad V; Maghzi AH
Mult Scler Relat Disord; 2020 Aug; 43():102222. PubMed ID: 32464586
[No Abstract] [Full Text] [Related]
8. Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.
Möhn N; Pul R; Kleinschnitz C; Prüss H; Witte T; Stangel M; Skripuletz T
Front Immunol; 2020; 11():1059. PubMed ID: 32477373
[TBL] [Abstract][Full Text] [Related]
9. Immunologic characterization of a immunosuppressed multiple sclerosis patient that recovered from SARS-CoV-2 infection.
Chiarini M; Paghera S; Moratto D; Rossi N; Giacomelli M; Badolato R; Capra R; Imberti L
J Neuroimmunol; 2020 Aug; 345():577282. PubMed ID: 32505908
[TBL] [Abstract][Full Text] [Related]
10. Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod.
Foerch C; Friedauer L; Bauer B; Wolf T; Adam EH
Mult Scler Relat Disord; 2020 Jul; 42():102180. PubMed ID: 32408155
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 and high-efficacy multiple sclerosis therapies: Time for business as usual?
Brownlee WJ
Mult Scler; 2020 Sep; 26(10):1267. PubMed ID: 32762499
[No Abstract] [Full Text] [Related]
12. Coronavirus disease 2019: favorable outcome in an immunosuppressed patient with multiple sclerosis.
Devogelaere J; D'hooghe MB; Vanderhauwaert F; D'haeseleer M
Neurol Sci; 2020 Aug; 41(8):1981-1983. PubMed ID: 32564270
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab.
Fernández-Díaz E; Gracia-Gil J; García-García JG; Palao M; Romero-Sánchez CM; Segura T
Mult Scler Relat Disord; 2020 Oct; 45():102402. PubMed ID: 32711297
[TBL] [Abstract][Full Text] [Related]
14. Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient.
Wurm H; Attfield K; Iversen AK; Gold R; Fugger L; Haghikia A
Mult Scler; 2020 Sep; 26(10):1261-1264. PubMed ID: 32762494
[TBL] [Abstract][Full Text] [Related]
15. Retinal cotton wool spot associated with cladribine therapy for multiple sclerosis.
Gummi R; Walsh RD; Ahmad B
Mult Scler Relat Disord; 2021 Feb; 48():102661. PubMed ID: 33321344
[TBL] [Abstract][Full Text] [Related]
16. The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic.
Baker D; Amor S; Kang AS; Schmierer K; Giovannoni G
Mult Scler Relat Disord; 2020 Aug; 43():102174. PubMed ID: 32464584
[TBL] [Abstract][Full Text] [Related]
17. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis.
Cook S; Leist T; Comi G; Montalban X; Giovannoni G; Nolting A; Hicking C; Galazka A; Sylvester E
Mult Scler Relat Disord; 2019 Apr; 29():157-167. PubMed ID: 30885374
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach.
Borriello G; Ianniello A
Mult Scler Relat Disord; 2020 Jun; 41():102165. PubMed ID: 32388451
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 and rheumatology: is shielding really necessary?
Amani L; Warraich R; Patel N; Tahir H
Br J Hosp Med (Lond); 2020 Jun; 81(6):1-3. PubMed ID: 32589537
[TBL] [Abstract][Full Text] [Related]
20. Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab.
Iannetta M; Cesta N; Stingone C; Malagnino V; Teti E; Vitale P; De Simone G; Rossi B; Ansaldo L; Compagno M; Spalliera I; Di Lorenzo A; Landi D; Nicoletti CG; Marfia GA; Andreoni M; Sarmati L
Mult Scler Relat Disord; 2020 Oct; 45():102442. PubMed ID: 32777745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
